Innate Pharma S.A.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan E. Dickinson
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 117, Avenue de Luminy Marseille PAC France 13009
- IPO Date
- Oct 17, 2019
- CIK
- 0001598599
- Website
- innate-pharma.com
- Similar Companies
- Business
- Innate Pharma S.A. (IPHA:EN Paris) is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company discovers and develops therapeutic antibodies targeting the innate immune system, including natural killer (NK) cell engagers and multispecific antibodies; its lead product candidate, IPH6501 (monalizumab), is a first-in-class anti-NKG2A antibody in Phase 3 trials for head and neck cancer in combination with other therapies; additional pipeline assets include IPH5301 (anti-CD39), IPH6208 (NKp46-based NK cell engager), and IPH6503 (anti-CD25); and it offers discovery services through its proprietary platforms such as the NK cell platform and antibody engineering technologies. Founded in 1999 and headquartered in Marseille, France, Innate Pharma operates primarily in Europe with clinical trials and partnerships extending to North America and Asia, targeting pharmaceutical companies and oncology patients through collaborations with major players like Sanofi and Bristol Myers Squibb. Recent developments include the advancement of IPH6501 into a Phase 3 trial in 2024 following positive Phase 2 data; a strategic licensing agreement with Sanofi for monalizumab development and commercialization rights in specific indications announced in late 2023; and the presentation of new preclinical data on IPH6208 at major oncology conferences in 2025, underscoring pipeline expansion amid ongoing cost-optimization measures.
Company News
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma Announces Conference Call and Webcast
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Outcome of Innate Pharma's 2026 Annual General Meeting
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
Innate Pharma to Participate in the D. Boral Capital Global Conference
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026